Apitegromab for infants with SMA under 2 years old
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a new medicine called apitegromab for babies under 2 years old with spinal muscular atrophy (SMA). It looks at whether the drug can help with muscle strength and reaching motor milestones like sitting or rolling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 2 years old at the start of the study.
- Your child must have been born at 35 weeks or later and weighed at least 4.4 pounds at birth.
- Your child must have a confirmed diagnosis of SMA type 5q (the most common form).
- Your child must already be taking or have taken an approved SMA treatment like Zolgensma, Spinraza, or Evrysdi.
- Your child must have motor delays due to SMA (like not reaching milestones or a low CHOP-INTEND score).
- Your child cannot need a feeding tube for most of their meals or have severe bone or joint problems that limit movement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
This trial is testing a one-time gene therapy drug for people with SMA type 3. The goal is to see if it can safely improve muscle function and strength.
This study tracks how well the gene therapy ITVISMA works in everyday medical practice for people with spinal muscular atrophy (SMA). It aims to see if the treatment is safe and effective in a real-world setting.
This trial tests a new gene therapy called GCB-001 for children with type 2 spinal muscular atrophy who can sit but not walk. It aims to improve muscle function and overall health.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.